Boys in school year 8, aged 12-13, are now eligible to receive the HPV vaccine alongside girls. This vaccine has been added to the routine immunisation schedule for this age group. Therefore, Dominic should receive the HPV vaccine this year. The meningitis ACWY and tetanus, diphtheria and polio vaccines are given at 14 years (school year 9) and are not applicable at this time. Dominic is up to date with his routine immunisations, including the MMR vaccine which is given at 1 year and again at 3 years and 4 months. The pneumococcal vaccine is only offered to 65-year-olds and is not relevant to Dominic’s current situation.

The human papillomavirus (HPV) is a known carcinogen that infects the skin and mucous membranes. There are numerous strains of HPV, with strains 6 and 11 causing genital warts and strains 16 and 18 linked to various cancers, particularly cervical cancer. HPV infection is responsible for over 99.7% of cervical cancers, and testing for HPV is now a crucial part of cervical cancer screening. Other cancers linked to HPV include anal, vulval, vaginal, mouth, and throat cancers. While there are other risk factors for developing cervical cancer, such as smoking and contraceptive pill use, HPV vaccination is an effective preventative measure.

The UK introduced an HPV vaccine in 2008, initially using Cervarix, which protected against HPV 16 and 18 but not 6 and 11. This decision was criticized due to the significant disease burden caused by genital warts. In 2012, Gardasil replaced Cervarix as the vaccine used, protecting against HPV 6, 11, 16, and 18. Initially given only to girls, boys were also offered the vaccine from September 2019. The vaccine is offered to all 12- and 13-year-olds in school Year 8, with the option for girls to receive a second dose between 6-24 months after the first. Men who have sex with men under the age of 45 are also recommended to receive the vaccine to protect against anal, throat, and penile cancers.

Injection site reactions are common with HPV vaccines. It should be noted that parents may not be able to prevent their daughter from receiving the vaccine, as information given to parents and available on the NHS website makes it clear that the vaccine may be administered against parental wishes.

According to NICE guidelines, if a child under 6 months old has a UTI that responds well to antibiotics within 48 hours, an ultrasound scan should be done within 6 weeks. However, if the UTI is atypical or recurrent, additional tests such as ultrasound during the acute infection, DMSA 4-6 months after the acute infection, and MCUG are recommended.

An atypical UTI may present with symptoms such as being seriously ill, poor urine flow, an abdominal or bladder mass, elevated creatinine, failure to respond to antibiotics within 48 hours, or non-E. coli organisms. Recurrent UTI is defined as having two or more episodes of UTI with acute pyelonephritis/upper urinary tract infection, one episode of UTI with acute pyelonephritis/upper urinary tract infection plus one or more episodes of UTI with cystitis/lower urinary tract infection, or three or more episodes of UTI with cystitis/lower urinary tract infection.

Urinary tract infections (UTIs) in children require investigation to identify any underlying causes and potential kidney damage. Unlike in adults, the development of a UTI in childhood may indicate renal scarring. The National Institute for Health and Care Excellence (NICE) recommends imaging the urinary tract for infants under six months who present with their first UTI and respond to treatment, within six weeks. Children over six months who respond to treatment do not require imaging unless there are features suggestive of an atypical infection, such as being seriously ill, having poor urine flow, an abdominal or bladder mass, raised creatinine, septicaemia, failure to respond to antibiotics within 48 hours, or infection with non-E. coli organisms.

Further investigations may include a urine microscopy and culture, as only 50% of children with a UTI have pyuria, making microscopy or dipstick of the urine inadequate for diagnosis. A static radioisotope scan, such as DMSA, can identify renal scars and should be done 4-6 months after the initial infection. Micturating cystourethrography (MCUG) can identify vesicoureteric reflux and is only recommended for infants under six months who present with atypical or recurrent infections.

Measles Presentation and Importance of Vaccination History

Measles typically begins with a prodromal phase that includes symptoms such as conjunctivitis, rhinitis, cough, and fever. By day four to five, an erythematous maculopapular rash appears, starting on the head and spreading to the trunk and limbs. The rash can become confluent as it progresses. Koplik spots, which are pathognomonic for measles, may appear before the rash.

It is crucial to obtain a vaccination history and check the oral mucosa when evaluating a patient with suspected measles. Additionally, good safety-netting is essential to ensure appropriate follow-up and management. By being aware of the typical presentation of measles and the importance of vaccination, healthcare providers can help prevent the spread of this highly contagious disease.

When a child has a fever, moderate or severe intercostal recession is a concerning symptom. This is considered a red flag according to NICE guidelines, which indicate a high risk of serious illness. Other red flag symptoms include those in the amber risk category, such as nasal flaring and a respiratory rate over 40 breaths per minute for children over 12 months old. A heart rate of 138 beats per minute is not a red flag symptom, but a heart rate over 140 beats per minute for children aged 2-5 years is considered an amber symptom. A temperature of 38°C or higher is only a red flag symptom for infants aged 0-3 months.

The NICE Feverish illness in children guidelines were introduced in 2007 and updated in 2013 to provide a ‘traffic light’ system for assessing the risk of febrile illness in children under 5 years old. The guidelines recommend recording the child’s temperature, heart rate, respiratory rate, and capillary refill time, as well as looking for signs of dehydration. Measuring temperature should be done with an electronic thermometer in the axilla for children under 4 weeks or with an electronic/chemical dot thermometer in the axilla or an infra-red tympanic thermometer. The risk stratification table categorizes children as green (low risk), amber (intermediate risk), or red (high risk) based on their symptoms. Management recommendations vary depending on the risk level, with green children managed at home, amber children provided with a safety net or referred to a specialist, and red children urgently referred to a specialist. The guidelines also advise against prescribing oral antibiotics without an apparent source of fever and note that a chest x-ray is not necessary if a child with suspected pneumonia is not being referred to the hospital.

If a child with bronchiolitis displays any high risk signs, it is important to admit them for support with feeding to prevent dehydration. The NICE CKS provides a comprehensive list of these signs, which include a respiratory rate exceeding 60 per minute, intermittent apnoea, grunting, moderate or severe chest in-drawing, cyanosis, pale, ashen, mottled or blue skin color, lack of response to social cues, inability to be roused or stay awake, and appearing ill. Reduced skin turgor is also a sign of dehydration to watch out for.

Understanding Bronchiolitis

Bronchiolitis is a condition that is characterized by inflammation of the bronchioles. It is a serious lower respiratory tract infection that is most common in children under the age of one year. The pathogen responsible for 75-80% of cases is respiratory syncytial virus (RSV), while other causes include mycoplasma and adenoviruses. Bronchiolitis is more serious in children with bronchopulmonary dysplasia, congenital heart disease, or cystic fibrosis.

The symptoms of bronchiolitis include coryzal symptoms, dry cough, increasing breathlessness, and wheezing. Fine inspiratory crackles may also be present. Children with bronchiolitis may experience feeding difficulties associated with increasing dyspnoea, which is often the reason for hospital admission.

Immediate referral to hospital is recommended if the child has apnoea, looks seriously unwell to a healthcare professional, has severe respiratory distress, central cyanosis, or persistent oxygen saturation of less than 92% when breathing air. Clinicians should consider referring to hospital if the child has a respiratory rate of over 60 breaths/minute, difficulty with breastfeeding or inadequate oral fluid intake, or clinical dehydration.

The investigation for bronchiolitis involves immunofluorescence of nasopharyngeal secretions, which may show RSV. Management of bronchiolitis is largely supportive, with humidified oxygen given via a head box if oxygen saturations are persistently < 92%. Nasogastric feeding may be needed if children cannot take enough fluid/feed by mouth, and suction is sometimes used for excessive upper airway secretions.

The NICE paediatric traffic light system identifies a respiratory rate of over 60 per minute as a red flag, regardless of age. Other symptoms that are considered amber or red flags include decreased urine output, dry mucous membranes, and a heart rate of over 150 beats per minute in 12-24-month-olds. A fever of over 39ºC is not an amber or red symptom, but it is considered an amber symptom in 3-6-month-olds and a red flag in children under 3 months.

The NICE Feverish illness in children guidelines were introduced in 2007 and updated in 2013 to provide a ‘traffic light’ system for assessing the risk of febrile illness in children under 5 years old. The guidelines recommend recording the child’s temperature, heart rate, respiratory rate, and capillary refill time, as well as looking for signs of dehydration. Measuring temperature should be done with an electronic thermometer in the axilla for children under 4 weeks or with an electronic/chemical dot thermometer in the axilla or an infra-red tympanic thermometer. The risk stratification table categorizes children as green (low risk), amber (intermediate risk), or red (high risk) based on their symptoms. Management recommendations vary depending on the risk level, with green children managed at home, amber children provided with a safety net or referred to a specialist, and red children urgently referred to a specialist. The guidelines also advise against prescribing oral antibiotics without an apparent source of fever and note that a chest x-ray is not necessary if a child with suspected pneumonia is not being referred to the hospital.

The recommended treatment for formula-fed infants with gastro-oesophageal reflux disease is to reduce their daily milk intake to 150ml/kg and offer more frequent, smaller feeds. This should be tried for 2 weeks, and if the baby is still experiencing discomfort, milk thickeners can be offered for 1-2 weeks. If this is not successful, a trial of alginate therapy should be attempted for 1-2 weeks. If this also fails, a 4-week trial of a proton pump inhibitor or histamine-2 receptor antagonist can be prescribed. Breastfed infants should first try a 1-2 week trial of alginate therapy.

Gastro-oesophageal reflux is a common cause of vomiting in infants, with around 40% of babies experiencing some degree of regurgitation. However, certain risk factors such as preterm delivery and neurological disorders can increase the likelihood of developing this condition. Symptoms typically appear before 8 weeks of age and include vomiting or regurgitation, milky vomits after feeds, and excessive crying during feeding. Diagnosis is usually made based on clinical observation.

Management of gastro-oesophageal reflux in infants involves advising parents on proper feeding positions, ensuring the infant is not overfed, and considering a trial of thickened formula or alginate therapy. However, proton pump inhibitors (PPIs) are not recommended as a first-line treatment for isolated symptoms of regurgitation. PPIs may be considered if the infant experiences unexplained feeding difficulties, distressed behavior, or faltering growth. Metoclopramide, a prokinetic agent, should only be used with specialist advice.

Complications of gastro-oesophageal reflux can include distress, failure to thrive, aspiration, frequent otitis media, and dental erosion in older children. If medical treatment is ineffective and severe complications arise, fundoplication may be considered. It is important for healthcare professionals to be aware of the risk factors, symptoms, and management options for gastro-oesophageal reflux in infants.

Common Infant Characteristics and Abnormalities

The following are common characteristics and abnormalities that may be observed in infants:

Unilateral Moro Reflex: A response to something that startles the infant, such as a loud noise or a sudden loss of support. Absence may indicate a profound disorder of the motor system, while persistence beyond four or five months of age occurs in infants with severe neurological defects.

Scattered Red Marks with Papules and Pustules on the Face and Trunk: This is toxic erythema of the newborn, a common finding in neonates. It doesn’t cause the child discomfort and usually lasts several days.

Fall in Weight from Birth Weight: Most babies lose about 10% of their birth weight after birth, but they usually regain this weight after about two weeks.

Pink Moist Granuloma in the Umbilicus: An overgrowth of granulation tissue that occurs after the cord has fallen off. The discharge from an umbilical granuloma may irritate the surrounding skin.

Single Palmar Crease: About 5% of newborns have a single palmar crease on at least one hand, frequently inherited as a familial trait. It is sometimes associated with Down and other syndromes, although other signs would point to these conditions.

The UK immunisation schedule recommends certain vaccines at different ages. At birth, the BCG vaccine is given if the baby is at risk of tuberculosis. At 2, 3, and 4 months, the ‘6-1 vaccine’ (diphtheria, tetanus, whooping cough, polio, Hib and hepatitis B) and oral rotavirus vaccine are given, along with Men B and PCV at specific intervals. At 12-13 months, the Hib/Men C, MMR, PCV, and Men B vaccines are given. At 3-4 years, the ‘4-in-1 Preschool booster’ (diphtheria, tetanus, whooping cough and polio) and MMR vaccines are given. At 12-13 years, the HPV vaccination is given, and at 13-18 years, the ‘3-in-1 teenage booster’ (tetanus, diphtheria and polio) and Men ACWY vaccines are given. Additionally, the flu vaccine is recommended annually for children aged 2-8 years.

It is important to note that the meningitis ACWY vaccine has replaced meningitis C for 13-18 year-olds due to an increased incidence of meningitis W disease in recent years. The ACWY vaccine is also offered to new students up to the age of 25 years at university. GP practices will automatically send letters inviting 17-and 18-year-olds in school year 13 to have the Men ACWY vaccine, while students going to university or college for the first time should contact their GP to have the vaccine before the start of the academic year.

The Men C vaccine used to be given at 3 months but has now been discontinued as there are almost no cases of Men C disease in babies or young children in the UK. All children will continue to be offered the Hib/Men C vaccine at one year of age, and the Men ACWY vaccine at 14 years of age to provide protection across all age groups.

Pregnant women between 16-32 weeks should receive both influenza and pertussis vaccines. The pertussis vaccine is typically part of the diphtheria, pertussis, and tetanus vaccination and is important for preventing severe illness and death in newborns. A hepatitis B booster is not necessary with either vaccine.

A vaccination programme for pregnant women was introduced in 2012 to combat an outbreak of whooping cough that resulted in the death of 14 newborn children. The vaccine is over 90% effective in preventing newborns from developing whooping cough. The programme was extended in 2014 due to uncertainty about future outbreaks. Pregnant women between 16-32 weeks are offered the vaccine.